Patents by Inventor Laurent Debarbieux
Laurent Debarbieux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11918613Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.Type: GrantFiled: June 21, 2021Date of Patent: March 5, 2024Assignees: FERRING B.V., INSTITUT PASTEURInventors: Pascal Danglas, Laurent Debarbieux
-
Publication number: 20210386805Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.Type: ApplicationFiled: June 21, 2021Publication date: December 16, 2021Applicants: FERRING B.V., INSTITUT PASTEURInventors: Pascal Danglas, Laurent Debarbieux
-
Patent number: 11041147Abstract: The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of ST131-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes ST131-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs.Type: GrantFiled: April 12, 2017Date of Patent: June 22, 2021Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS DIDEROT—PARIS 7, UNIVERSITÉ PARIS XIII PARIS-NORDInventors: Jean-Damien Ricard, Olivier Clermont, Laurent Debarbieux, Erick Denamur, Nicolas Dufour
-
Patent number: 11040078Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.Type: GrantFiled: April 30, 2014Date of Patent: June 22, 2021Assignees: FERRING B.V., INSTITUT PASTEURInventors: Pascal Danglas, Laurent Debarbieux
-
Publication number: 20190120838Abstract: The present invention relates to methods and kits for the rapid detection of the Escherichia coli O25b-ST131 clone. The inventors have isolated a podoviridae bacteriophage (LM33_P1) infecting the E. coli strain LM33 isolated from ventilator associated pneumonia and which belongs to clone STI3I-025b. By testing different strains of E coli belonging to 129 others various distinct serotypes (including twelve O25a) the inventors found that bacteriophage LM33_P1 is able to infect exclusively O25b strains (none of non-O25b strains could be infected by LM33_P1). The inventors have determined that the specificity displayed by bacteriophage LM33_P1 to infect only 025b serotype strains is based on a very specific polypeptide (Gp17) used by LM33_P1 to attach the bacterial cell via LPS molecule. In particular, the present invention relates to a polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence set forth in SEQ ID NO:1.Type: ApplicationFiled: April 12, 2017Publication date: April 25, 2019Inventors: Jean-Damien RICARD, Nicolas DUFOUR, Erick DENAMUR, Laurent DEBARBIEUX, Olivier CLERMONT
-
Publication number: 20190119652Abstract: The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of STl31-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes STI31-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs.Type: ApplicationFiled: April 12, 2017Publication date: April 25, 2019Applicants: NSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS DIDEROT - PARIS 7, INSTITUT PASTEUR, UNIVERSITÉ PARIS XIII PARIS-NORDInventors: Jean-Damien RICARD, Olivier CLERMONT, Laurent DEBARBIEUX, Erick DENAMUR, Nicolas DUFOUR
-
Publication number: 20170108442Abstract: The invention relates to a new method for generating a luminescent signal, which is based on an enzyme-independent photon emission mechanism (EiPE), whereby luminescent light is generated when a bioluminescent substrate interact with a physical surface in the absence of any catalytic enzyme. In particular embodiments, the method is used to stimulate light emission by fluorescent molecules. The invention relates also to kits for implementing a method according to the present invention and to the use of a bioluminescent substrate, in the presence of a physical surface, to produce a luminescent signal in the absence of enzymatic catalyst.Type: ApplicationFiled: April 7, 2015Publication date: April 20, 2017Applicant: Institut PasteurInventors: Joseph Dragavon, Alexandra Holland, Abdessalem Rekiki, Laurent Debarbieux, Règis Tournebize, Spencer Shorte
-
Publication number: 20160143965Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.Type: ApplicationFiled: April 30, 2014Publication date: May 26, 2016Applicants: FERRING B.V., INSTITUT PASTEURInventors: Pascal Danglas, Laurent Debarbieux